Updated statistical data for malignant melanoma in Japan

Ishihara, Kazuyuki; Saida, Toshiaki; Yamamoto, Akifumi

doi:10.1007/pl00012091

Cited by 123 publications

(127 citation statements)

References 4 publications

Supporting

Mentioning

116

Contrasting

Unclassified

Order By: Relevance

“…In a small South African study of 40 people of mixed ancestry with melanoma, ALM was the most common subtype (32.5%; ref. 16), and a similar preponderance of ALM (49%) was found in Japan (17). The current study presents a subtype distribution similar to those above.…”

Section: Discussionsupporting

confidence: 88%

Melanoma in Maori, Asian, and Pacific Peoples in New Zealand

Sneyd

Cox

2009

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 88%

Melanoma in Maori, Asian, and Pacific Peoples in New Zealand

Sneyd

Cox

2009

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…More importantly, due to the difference of predominant melanoma subtypes between Caucasians (mainly cutaneous melanomas) and Asians (mainly acral and mucosal melanomas; refs. [42][43][44][45], mTOR aberrations in acral and mucosal melanomas remain largely unknown. Our data have thus greatly filled this gap.…”

Section: Discussionmentioning

confidence: 99%

Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Kong

et al. 2016

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: mTOR is a validated target in cancer. It remains to be determined whether melanoma patients bearing mTOR mutation could be selected for treatment with PI3K–AKT–mTOR pathway inhibitors. Experimental Design: A total of 412 melanoma samples were included. Gene aberrations in all exons of mTOR were detected by Sanger sequencing and confirmed by using Agilent's SureSelect Target Enrichment System. HEK293T cells stably expressing mTOR mutants were constructed by using transcription activator-like effector nucleases technique. Function of mTOR mutants and in vitro sensitivity of gain-of-function mTOR mutations to PI3K–AKT–mTOR pathway inhibitors were analyzed. Results: The overall incidence of somatic nonsynonymous mutations of mTOR was 10.4% (43/412). mTOR nonsynonymous mutations were relatively more frequent in acral (11.0%) and mucosal (14.3%) melanomas than in chronic sun-induced damage (CSD; 6.7%) and non-CSD (3.4%) melanomas. Of the 43 cases with mTOR mutations, 41 different mutations were detected, affecting 25 different exons. The median survival time for melanoma patients with mTOR nonsynonymous mutation was significantly shorter than that for patients without mTOR nonsynonymous mutation (P = 0.028). Transient expression of mTOR mutants in HEK293T cells strongly activated the mTOR–p70S6K pathway. In HEK293T cells with stable expression of H1968Y or P2213S mTOR mutants, LY294002 and AZD5363 showed higher potency than temsirolimus or BYL719 in inhibiting the PI3K–AKT–mTOR pathway and cell proliferation. Conclusions: mTOR nonsynonymous mutations are frequent in melanoma patients. mTOR nonsynonymous mutation may predict a worse prognosis of melanoma. Clinical trials with PI3K–AKT–mTOR pathway inhibitors may be beneficial for melanoma patients with specific mTOR mutations. Clin Cancer Res; 22(4); 1018–27. ©2015 AACR.

show abstract

“…Apesar de ser pouco frequente nos caucasianos (2-8%), é no entanto, o tipo de melanoma com maior prevalência nos negros (até 70%) e asiáticos (até 45%). 5,23,24 Neste estudo todos os doentes eram caucasianos, mas não foi possível obter informação relativa ao fototipo.…”

unclassified

Melanoma Maligno Cutâneo: Estudo Retrospetivo de Sete Anos (2006-2012)

Moreira

Azevedo

et al. 2014

Acta Med Port

View full text Add to dashboard Cite

Acta Med Port 2014 Jul-Aug;27(4):480-488 RESUMOIntrodução: O melanoma maligno é a neoplasia cutânea mais agressiva, e a sua incidência tem vindo a aumentar nas últimas déca-das. A possibilidade de cura depende de um diagnóstico atempado, sendo fundamental o conhecimento da sua epidemiologia para a implementação de programas de prevenção primária e deteção precoce do melanoma. ABSTRACTIntroduction: Malignant melanoma is the most aggressive skin cancer and its incidence has been increasing in recent decades. The cure depends on early diagnosis and understanding melanoma epidemiology is of great importance for the implementation of programs of primary prevention and early detection. Material and Methods:We reviewed the clinical cases of primary cutaneous malignant melanoma diagnosed between January 2006 and December 2012 at Centro Hospitalar de São João, in Porto.Results: An overall of 148 cases of melanoma were analyzed and a female predominance was observed (ratio F:M -1.6:1). The average age at diagnosis was 61 years. The locations most frequently affected were the lower limbs and trunk. In males the back was the most frequently involved, while in females the lesions occurred preferentially in the legs. Superficial spreading melanoma prevailed in almost all age groups. There was a predominance of thin melanomas and the mitotic index was intermediate (1-6 mitoses/ mm 2 ) in most patients. The ulceration was present in 22.3% of cases and prevailed in thick melanomas as well in nodular subtype. Most patients present at stage IA. There was progression to metastatic disease in 20 patients. Discussion: The profile of patients with cutaneous melanoma in Centro Hospitalar de São João has characteristics relatively similar to those described in the literature. Conclusion: The prevalence of thin melanomas, generally with a better outcome, is probably the result of an earlier detection.

show abstract

Updated statistical data for malignant melanoma in Japan

Abstract: The prognosis of advanced melanoma is poor, as it is highly resistant to chemotherapy. Thus, to improve the prognosis, early detection is mandatory, and this is possible because this neoplasm appears as a distinctive pigmented lesion on the skin.

Cited by 123 publications

References 4 publications

Melanoma in Maori, Asian, and Pacific Peoples in New Zealand

Melanoma in Maori, Asian, and Pacific Peoples in New Zealand

Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Melanoma Maligno Cutâneo: Estudo Retrospetivo de Sete Anos (2006-2012)

Contact Info

Product

Resources

About